0.01
0.00%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Botanix Pharmaceuticals
Its shares trade on ASX under the ticker BOT.AX. It has been listed since 24 January 1985. In the fiscal year to 30 June 2026, it reported revenue of A$34.5m and a net loss of A$69.8m. At that date it held total assets of A$106.0m and shareholders' equity of A$63.5m.
Botanix Pharmaceuticals Ltd. engages in the development of therapeutics for the treatment of skin diseases. The company is headquartered in Perth, Western Australia. The firm focuses on developing medical dermatology products for dermatologists and their patients. Its segments include Research & Development and Corporate. The firm's products and pipeline products are all based on drug delivery technology known as Permetrex, which helps solve the challenge of delivering active pharmaceutical ingredients across the skin. The firm's products, which are under development, are focused on modulating the body's endocannabinoid system of receptors which regulates skin function, growth and renewal. Its product pipeline includes BTX1503, BTX1308 and BTX1204. Its BTX1503 is a transdermal gel formulation used for the treatment of serious acne in adults and teenagers. Its BTX1308 is a transdermal gel formulation used for the treatment of plaque psoriasis. Its BTX1204 is a transdermal gel formation used for the treatment of atopic dermititis.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 24 Jan 1985
- Employees
- 1
- Website
- botanixpharma.com ↗
Leadership
Pay as last reported
- Mr. Vincent IppolitoExecutive Chairman of the Board, President, since 2019A$709,030
- Mr. Howie McKibbonChief Executive OfficerA$207,406
- Mr. Graeme MorisseyChief Financial Officer
- Dr. William BoschExecutive Director, since 2016A$203,537
- Mr. Matthew CallahanExecutive Director, since 2016A$347,959
- Ms. Susan ParkCompany Secretary
- Mr. Daniel SharpNon-Executive DirectorA$49,665
- Dr. Stewart WasherNon-Executive DirectorA$129,525
- Ms. Hannah HowlettInvestor Relations, since 2022
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Botanix Pharmaceuticals Ltd has a strong research and development team that is dedicated to discovering innovative solutions in the field of pharmaceuticals. This expertise allows the company to develop unique products with great potential for success in the market.
- The company has a portfolio of intellectual property rights and patents, giving it a competitive advantage and protecting its products from potential competitors.
Weaknesses
- Botanix Pharmaceuticals Ltd operates in a highly regulated industry, which presents challenges in terms of compliance with strict government regulations. This can result in delays and increased costs in the development and approval process.
- The company heavily relies on external funding to support its research and development efforts, making it vulnerable to changes in investor sentiment or the availability of capital.
Opportunities
- There is a growing demand for natural and plant-based pharmaceutical products, which aligns with Botanix Pharmaceuticals Ltd's focus on developing treatments derived from botanical sources. This presents an opportunity for the company to capitalize on this trend and gain a significant market share.
- The increasing awareness and acceptance of alternative and complementary medicine provide an opportunity for Botanix Pharmaceuticals Ltd to position its products as viable alternatives to traditional pharmaceuticals.
Threats
- The pharmaceutical industry is highly competitive, with many established players dominating the market. Botanix Pharmaceuticals Ltd faces the threat of intense competition from both traditional pharmaceutical companies and other biotech firms.
- There is also a risk of potential side effects or adverse reactions associated with the use of botanical products. Negative publicity or regulatory concerns related to safety could significantly impact the company's reputation and market position.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.